Biomedical Engineering Reference
In-Depth Information
51. Mitchell JP (2006) Good practices of qualifying cascade impactors (CIs): a survey of members
of the European Pharmaceutical Aerosol Group (EPAG). Drug Delivery to the Lungs-16, The
Aerosol Society, London, UK, pp. 189-192, abstract in. J Aerosol Med 19(2):232
52. Dolovich M, Rhem R (1998) Impact of oropharyngeal deposition on inhaled dose. J Aerosol
Med 11(S1):S112-S115
53. Hickey AJ, Evans RM (1996) Aerosol generation for propellant-driven metered dose inhalers.
In: Hickey AJ (ed) Inhalation aerosols: physical and biological basis for therapy. Dekker, New
York, NY, pp 417-439
54. Stein SW, Gabrio BJ (2000) Understanding throat deposition during cascade impactor testing.
In: Dalby RN, Byron PR, Farr SJ, Peart J (eds) Respiratory drug delivery VII. Serentec Press,
Raleigh, NC, pp 573-576
55. Zhou Y, Sun J, Cheng Y-S (2011) Comparison of deposition in the USP and physical mouth-
throat models with solid and liquid particles. J Aerosol Med Pulm Drug Deliv 24(6):277-284
56. Dunbar CA, Hickey AJ (2000) Evaluation of probability density functions to approximate
particle size distributions of representative pharmaceutical inhalers. J Aerosol Sci
31:813-831
57. Roberts DL, Romay FA, Marple VA, Miller NC (2000) A high-capacity pre-separator for
cascade impactors. In: Dalby RN, Byron PR, Farr SJ, Peart J (eds) Respiratory drug delivery
VII. Serentec Press, Raleigh, NC, pp 443-445
58. Mitchell JP, Costa PA, Waters S (1988) An assessment of an Andersen Mark-II cascade impac-
tor. J Aerosol Sci 19(2):213-221
59. Mitchell JP, Nagel MW (2007) Valved holding chambers (VHCs) for use with pressurized
metered-dose inhalers (MDIs): a review of causes of inconsistent medication delivery. Prim
Care Respir J 16(4):207-214
60. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G
(2005) Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest
127(1):335-371
61. Rubin BK, Fink JB (2005) Optimizing aerosol delivery by pressurized metered-dose inhaler.
Respir Care 50(9):1191-1200
62. Canadian Standards Association (CSA) (2008) Spacers and holding chambers for use with
metered-dose inhalers. Mississauga, Ontario. CAN/CSA/Z264.1-02:2008 (revised). Available
at: http://www.shopcsa.ca/onlinestore/GetCatalogItemDetails.asp?mat=2013981
63. Dolovich MB, Mitchell JP (2004) Canadian Standards Association standard CAN/CSA/
Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pres-
surized metered-dose inhalers. Can Respir J 11(7):489-495
64. Mitchell JP, Poochikian G, Hickey AJ, Suggett J, Curry P, Tougas T (2011) In vitro assessment
of spacers and valved holding chambers used with pressurized metered-dose inhalers: the need
for a USP chapter with clinically relevant test methods. Pharm Forum 37(4). On-line at: http://
www.usppf.com/pf/pub/index.html . Visited 3 Jan 2012
65. European Medicines Agency (EMA) (2009) Guideline on the requirements for clinical docu-
mentation for orally inhaled products (OIP) including the requirements for demonstration of
therapeutic equivalence between two inhaled products for use in the treatment of asthma and
chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma
in children and adolescents. CPMP/EWP/4151/00 Rev. 1. London
66. Nagel MW, Schmidt JN, Doyle CC, Varallo VM, Mitchell JP (2003) Delay testing of valved
holding chambers (VHCs) with a new apparatus. Drug Delivery to the Lungs-14, The Aerosol
Society, London, pp 79-82
67. Rau JL, Coppolo DP, Nagel MW, Avvakoumova VA, Doyle CC, Wiersema KJ, Mitchell JP
(2006) The importance of nonelectrostatic materials in holding chambers for delivery of
hydrofluoroalkane albuterol. Respir Care 51(5):503-510
68. Foss SA, Keppel JW (1999) In vitro testing of MDI spacers: a technique for measuring respi-
rable dose output with actuation in-phase or out-of-phase with inhalation. Respir Care
44(12):1474-1485
Search WWH ::




Custom Search